The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study.
 
Yuankai Shi
No Relationships to Disclose
 
Gongyan Chen
No Relationships to Disclose
 
Xiang Wang
No Relationships to Disclose
 
Yunpeng Liu
No Relationships to Disclose
 
Lin Wu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Hengrui Pharmaceutical; Innovent Biologics; Lilly; Merck; MSD; Pfizer; Roche
 
Yanrong Hao
No Relationships to Disclose
 
Chunling Liu
No Relationships to Disclose
 
Shuyang Zhu
No Relationships to Disclose
 
Xiaodong Zhang
No Relationships to Disclose
 
Yuping Li
No Relationships to Disclose
 
Jiwei Liu
No Relationships to Disclose
 
Lejie Cao
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Hui Zhao
No Relationships to Disclose
 
Shucai Zhang
No Relationships to Disclose
 
Ai-min Zang
No Relationships to Disclose
 
Jiuwei Cui
No Relationships to Disclose
 
Jian Feng
No Relationships to Disclose
 
Nong Yang
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma
 
Jie Hu
Employment - Shanghai Allist Pharmaceuticals
Leadership - Shanghai Allist Pharmaceuticals
Stock and Other Ownership Interests - Shanghai Allist Pharmaceuticals